Pathophysiological Mapping of Experimental Heart Failure: Left and Right Ventricular Remodeling in Transverse Aortic Constriction Is Temporally, Kinetically and Structurally Distinct

Mathew J. Platt1,2†, Jason S. Huber1,2†, Nadya Romanova1,2, Keith R. Brunt2,3 and Jeremy A. Simpson1,2*

1 Department of Human Health & Nutritional Sciences, University of Guelph, Guelph, ON, Canada, 2 IMPART Team Canada Investigator Network, Saint John, NB, Canada, 3 Department of Pharmacology, Dalhousie Medicine New Brunswick, Saint John, NB, Canada

A growing proportion of heart failure (HF) patients present with impairments in both ventricles. Experimental pressure-overload (i.e., transverse aortic constriction, TAC) induces left ventricle (LV) hypertrophy and failure, as well as right ventricle (RV) dysfunction. However, little is known about the coordinated progression of biventricular dysfunction that occurs in TAC. Here we investigated the time course of systolic and diastolic function in both the LV and RV concurrently to improve our understanding of the chronology of events in TAC. Hemodynamic, histological, and morphometric assessments were obtained from the LV and RV at 2, 4, 9, and 18 weeks post-surgery.

Results: Systolic pressures peaked in both ventricles at 4 weeks, thereafter steadily declining in the LV, while remaining elevated in the RV. The LV and RV followed different structural and functional timelines, suggesting the patterns in one ventricle are independent from the opposing ventricle. RV hypertrophy/fibrosis and pulmonary arterial remodeling confirmed a progressive right-sided pathology. We further identified both compensation and decompensation in the LV with persistent concentric hypertrophy in both phases. Finally, diastolic impairments in both ventricles manifested as an intricate progression of multiple parameters that were not in agreement until overt systolic failure was evident.

Conclusion: We establish pulmonary hypertension was secondary to LV dysfunction, confirming TAC is a model of type II pulmonary hypertension. This study also challenges some common assumptions in experimental HF (e.g., the relationship between fibrosis and filling pressure) while addressing a knowledge gap with respect to temporality of RV remodeling in pressure-overload.

Keywords: diastolic dysfunction, pulmonary hypertension, left heart disease, concentric remodeling, mouse models

Abbreviations: BW, body weight; CSA, cross-sectional area; EDP, End Diastolic Pressure; HF, heart failure; HW, heart weight; LV, left ventricle; LVP, left ventricular pressure; RV, right ventricle; RVP, right ventricular pressure; TAC, transverse aortic constriction; TL, tibia length.
INTRODUCTION

Heart failure (HF), a chronic condition characterized by the inability of the heart to meet the metabolic demands of the body, is an increasing epidemic and a leading cause of mortality in the developed world (Benjamin et al., 2017). As the general population continues to age, the prevalence of HF will increase (Heidenreich et al., 2011). HF can develop acutely (e.g., infarction, broken heart syndrome, drug overdose) or over years as a result of chronic stress (e.g., hypertension, atherosclerosis, diabetes, cardiomyopathy). While all HF is progressive, each cause has defining characteristics that manifest in their own time-frame for reasons that are not always expected or explainable. Unfortunately, the majority of clinical knowledge on this progression is either retrospective or derived from late-stage patients only after years of remodeling precipitate symptoms. Alternatively, animal models are used to investigate the chronology of cardiac events to a particular stress over time. Temporal studies in animal models provide insight into the time course of remodeling patterns (Mirskey et al., 1983; Inoko et al., 1994; Klotz et al., 2006), and are valuable in the search for disease mechanisms and treatment targets (Foster et al., 2017).

Transverse aortic constriction (TAC) was developed to investigate the left ventricle (LV) response to pressure-overload (Rockman et al., 1991) and is suggested as a model of pulmonary hypertension (Chen et al., 2012; Mohammed et al., 2012; van Nierop et al., 2013). From a clinical standpoint, there is a growing understanding that poor right ventricle (RV) function is an independent predictor of HF patient outcomes (Ghio et al., 2001; Karaye et al., 2010; Meyer et al., 2010). At the same time, an increasing proportion of patients with LV dysfunction are also being diagnosed with concurrent RV dysfunction (Zakeri and Mohammed, 2015; Rosenkranz et al., 2016). Experimental models like TAC recapitulate this 'biventricular phenotype' and are therefore of growing importance to pre-clinical investigations. In this study, we address a knowledge gap in the TAC model with respect to the chronology of hemodynamic, morphological and kinetic changes in both ventricles as compared to the LV. We hypothesize that pulmonary hypertension and the associated RV pathology will occur secondary to LV dysfunction (i.e., type II pulmonary hypertension), and that the patterns of remodeling will be distinct from those observed in the LV.

Diastolic dysfunction is growing concern requiring more research, given that it is more prevalent than systolic dysfunction in HF patients (Hogg et al., 2004), the general population (Fischer et al., 2003; Wan et al., 2014), and particularly in women (Ferreira et al., 2015). There are numerous parameters used to assess cardiac diastole, however, no studies have compared these different indices for their relative capacity to grade diastolic dysfunction in a model of HF over time. This makes comparisons between experimental models using different parameters difficult to interpret. In the present study, we asked the question: do invasive indices of diastolic function (i.e., dP/dt\text{min}, filling pressures, Tau) agree over time in TAC? We hypothesize that different indices of diastolic function will progress independently given the complexity of cardiac diastole and, likely, the different aspects captured by each parameter.

The salient findings in this study are: (1) Pulmonary hypertension was secondary to the increase in LV filling pressure and dysfunction, and RV and pulmonary vasculature remodeling was temporally distinct from the LV. (2) Determining the severity of diastolic dysfunction in either ventricle over time was complex, given that diastolic parameters were not in agreement until overt systolic dysfunction was apparent. And (3) the time course of structural and kinetic changes in both ventricles was interesting: interstitial fibrosis did not correlate with filling pressures in either ventricle, LV pressures did not predict RV pressures, and hypertrophy in the LV and RV had both early and late stage phenotypes that were not predictable from prevailing hemodynamics. Together, this study improves our understanding of the biventricular response to pressure-overload and firmly establishes TAC as a model of type II pulmonary hypertension.

MATERIALS AND METHODS

Surgical Model

Briefly, 9-week-old male (32–40 g) CD-1 mice (Charles River Laboratory International Inc.), were anesthetized with an isoflurane/oxygen mix (2%:100%), intubated and connected to a ventilator (Harvard Apparatus). Mice were ventilated at 200 breaths per minute at 300 μL per breath. TAC was done as previously described (Allwood et al., 2014; Foster et al., 2017). Briefly, the 2nd and 3rd ribs were separated from their cartilaginous connections with the sternum to expose the aortic arch. The transverse aorta was isolated and constricted to 26-gauge blunted needle with 7-0 silk thread. Sham surgery was similar to TAC, absent only the placement of the 7-0 thread. All mice were housed on a 12-h light/dark cycle and with food and water ad libitum. This study was approved by the Animal Care Committee at the University of Guelph and all experiments were carried out in accordance with the guidelines from the Canadian Council on Animal Care.

Echocardiographic Analysis

Mice were anesthetized with an isoflurane/oxygen mix (2%:100%). Echocardiography was performed using the Vevo2100 system (VisualSonics Inc., Toronto, ON, Canada) with the 40 MHz MS550D ultrasound transducer. Mice were kept at 37°C throughout data collection using a TH-5 rectal probe thermometer (Physiotemp Instruments LLC, Clifton, NJ, United States). Acquired M-mode images were analyzed with the LV-trace function from the cardiac package (VisualSonics Inc., Toronto, ON, Canada), and data was obtained over at least 5 heart beats as previously described (Platt et al., 2017). All measurements were made between noon and 5 pm.

Hemodynamic Analysis

Mice were sacrificed at 2, 4, 9, or 18 weeks after TAC or sham surgery. Again, an isoflurane/oxygen mix (2%:100%) was...
used, and again mice were kept at 37°C while a 1.2F catheter (FTS-1211B-0018; Scisense Inc., London, ON, Canada) was inserted into the RV via the right jugular and into the LV via the right carotid. Hemodynamic signals were digitized at a sampling rate of 2 kHz and recorded using iWorx® analytic software (Labscribe2, Dover, NH, United States). Data sets were analyzed with the removal of respiration artifacts. The presence of pulmonary hypertension was determined using the 99th percentile upper reference limit (i.e., greater than three standard deviations above the mean right ventricular systolic pressure in sham mice). Thus, 32.5 mmHg was deemed the physiological threshold for pulmonary hypertension in our model. Animals designated for morphometric analysis had organs removed, cleaned and weighed. Animals designated for histological analysis were exsanguinated and 10 mL of 1x PBS, 10 mL of 0.5 mol L\(^{-1}\) KCl, and 10 mL of 10% buffered formalin (VWR, Mississauga, ON, Canada) were perfused through the right carotid artery. Tissues were harvested, stored in 10% saturated picric acid solution and 0.5 g of Direct Red 80 from Sigma Aldrich), to visualize interstitial fibrosis of muscularized to non-muscularized arteries (Sheikh et al., 2014). This stains elastic fibers and stain was prepared with reagents obtained from VWR (Mississauga, ON, Canada). This stains elastic fibers and collagen fibers red and cytoplasm yellow. (Sigma Aldrich) to assess cardiomyocyte cross-sectional area (staining cytoplasm yellow and collagen red), or Wheat Germ using Cell Sense software (Olympus, Tokyo, Japan). CSA was quantified only from cardiomyocytes with centralized nuclei. For analysis of lung tissue, fresh Verhoff Van Geison stain was prepared with reagents obtained from VWR (Mississauga, ON, Canada). This stains elastic fibers and nuclei purple/black, collagen fibers red and cytoplasm yellow. The medial thickness of muscularized arteries was expressed as a percentage of external medial diameter. Arteries with internal diameters < 35 µm were selected for quantifying the ratio of muscularized to non-muscularized arteries (Sheikh et al., 2014).

**Statistical Methods**
All results are expressed as means ± SE unless otherwise indicated. Statistical analysis was performed using Prism (Graphpad Software Inc.). Statistical significance between sham and TAC mice at individual time-points was determined using the two-tailed Students \(t\)-test. A one-way ANOVA (Tukeys post hoc) was used to determine differences within one group over 18 weeks as all measures were terminal. Differences between sequential time-points were subsequently determined using a two-tailed Students \(t\)-test. Regression analyses were done with Prism 6.0. The threshold for significance was \(p < 0.05\) in all cases unless otherwise specified.

**RESULTS**

**RV Dysfunction Develops Secondary to LV Dysfunction, With a Complex Progression of Diastolic Dysfunction in Both Ventricles**

To account for changes in function as the mice aged, TAC’s were compared to age-matched surgical shams at all time-points. Representative tracings and a summary of invasive hemodynamic function over 18 weeks of TAC are presented in Figure 1 and Table 1 (for sham data, see Table 2).

LV pressure (LVP; Figure 1C) peaked at 4 weeks before progressively declining toward sham values by 18 weeks. RV pressure (RVP; Figure 1I) peaked at 4 weeks, but unlike the LVP, plateaued from 9 to 18 weeks. Of importance for the chronology of this model, pulmonary hypertension did not develop until 4 weeks. Only 11% (1/9) of TAC mice at 2 weeks had pulmonary hypertension. By 4 weeks, incidence of pulmonary hypertension rose to 90% (9/10) and was 75% thereafter (16/21).

To evaluate systolic function, the first positive derivative of ventricular pressure (dP/dt\(_{\text{max}}\)) was used as an index of contractility (Figures 1D,J). LV dP/dt\(_{\text{max}}\) initially decreased at 2 weeks before rebounding by 4 weeks and progressively declining thereafter. In the RV, dP/dt\(_{\text{max}}\) was unchanged until increasing at 4 weeks before also declining thereafter.

To assess diastolic dysfunction, we used three different indices: the first negative derivative of ventricular pressure (dP/dt\(_{\text{min}}\)), end diastolic pressure (EDP) and two methods to calculate the relaxation time constant (i.e., Tau Weiss; \(\text{Tau}_\text{W}\)) and Tau Glantz; \(\text{Tau}_\text{G}\)) (Figures 1E–H,K–N and Table 1). LV EDP increased ~400% by 2 weeks and plateaued thereafter (Figure 1E). LV dP/dt\(_{\text{min}}\) followed the same trend as LV dP/dt\(_{\text{max}}\), initially reduced at 2 weeks, normalizing by 4 weeks and then progressively declining out to 18 weeks (Figure 1F). LV Tau\(_\text{W}\) increased only by 18 weeks (Figure 1G) while Tau\(_\text{G}\) was elevated both at 2 and 18 weeks (Figure 1H). In the RV, EDP initially increased by 4 weeks before partially returning toward sham levels at an elevated plateau between 9 and 18 weeks (Figure 1I). RV dP/dt\(_{\text{min}}\) followed the same pattern as RV dP/dt\(_{\text{max}}\), increasing at 4 weeks before declining out to 18 weeks (Figure 1L). RV Tau\(_\text{G}\) increased at 2 weeks (Figure 1N) while Tau\(_\text{W}\) increased at 4 weeks (Figure 1M); both stayed elevated from sham thereafter.

In sham mice, LV and RV pressure, as well as systolic and diastolic function also changed over 18 weeks. LVP increased by ~20%, while RVP increased by ~10% (Figures 1C,I). Interestingly, while LV dP/dt\(_{\text{max}}\) was stable (changing by <10% over 18 weeks), RV dP/dt\(_{\text{max}}\) increased ~30% between 2 and 9 weeks (Figures 1D,J). In the LV, most measures of diastolic function declined by 18 weeks (EDP and Tau\(_\text{G}\) increased by ~60%, while dP/dt\(_{\text{min}}\) declined by 10%), yet Tau\(_\text{W}\) remained unchanged (Table 2). Alternatively, in the RV, measures of diastolic function either improved (dP/dt\(_{\text{min}}\) increased by ~40%) or were unchanged (EDP, Tau\(_\text{G}\) and Tau\(_\text{W}\) were stable; Table 2).
Interstitial Fibrosis Did Not Correlate With Diastolic Function in Either Ventricle Over Time

Elevations in EDP are sometimes reconciled as the product of fibrotic remodeling. To investigate this relationship over time in our model, histological sections of the ventricles were stained with PSR (Figure 2A). In the LV, interstitial fibrosis progressively increased over 18 weeks, initially increasing \(~8\) fold by 2 weeks with a further \(~50\)% increase out to 18 weeks (Figure 2B). In the RV, interstitial fibrosis increased linearly \(~10\) fold by 4 weeks, stabilizing thereafter (Figure 2B).

Regression did not find a significant non-zero relationship between EDP and fibrosis over time in either the LV (Figure 2C) or RV (Figure 2D). Of an interesting note was that interstitial fibrosis increased \(~500\)% in the RV by 2 weeks without a concurrent change in RV EDP.

To investigate if fibrosis correlated with any other parameter of diastolic function, we compared the relationship between fibrosis and \(\frac{dp}{dt_{\text{min}}}\), \(\tau_{\text{G}}\) and \(\tau_{\text{W}}\) in both the LV (Figures 2E–G) and RV (Figures 2H–J). No parameter consistently correlated over time. At best, in the RV only, there was a dichotomy between early and late fibrosis and diastolic dysfunction.

Pressure-Overload Resulted in Divergent Patterns of Hypertrophy Between the LV and RV Over Time

To investigate the hypertrophic response following LV pressure-overload, whole hearts (ventricles, septum and atria) were
TABLE 1 | Invasive hemodynamics from the left and right ventricles in TAC.

<table>
<thead>
<tr>
<th></th>
<th>Pre Surgery (n = 9)</th>
<th>2 weeks (n = 24)</th>
<th>4 weeks (n = 16)</th>
<th>9 weeks (n = 16)</th>
<th>18 weeks (n = 22)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Left Ventricle (LV)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVP (mmHg)</td>
<td>95 ± 2</td>
<td>144 ± 3</td>
<td>169 ± 4</td>
<td>146 ± 3</td>
<td>118 ± 5</td>
</tr>
<tr>
<td>EDP (mmHg)</td>
<td>4.6 ± 1.4</td>
<td>20.2 ± 1.2</td>
<td>21.7 ± 2.4</td>
<td>17.2 ± 2.8</td>
<td>22.3 ± 1.1</td>
</tr>
<tr>
<td>LV min Pressure (mmHg)</td>
<td>−2.8 ± 0.9</td>
<td>9.0 ± 1.0</td>
<td>7.1 ± 1.6</td>
<td>7.5 ± 2.1</td>
<td>13.1 ± 1.2</td>
</tr>
<tr>
<td>Systolic Pressure (mmHg)</td>
<td>88 ± 3</td>
<td>142 ± 2</td>
<td>163 ± 5</td>
<td>144 ± 3</td>
<td>118 ± 4</td>
</tr>
<tr>
<td>Diastolic Pressure (mmHg)</td>
<td>61 ± 3</td>
<td>65 ± 2</td>
<td>61 ± 3</td>
<td>57 ± 3</td>
<td>57 ± 3</td>
</tr>
<tr>
<td>dP/dt@LVP40 (mmHg/s)</td>
<td>9838 ± 388</td>
<td>7685 ± 191</td>
<td>9652 ± 391</td>
<td>8259 ± 486</td>
<td>6148 ± 332</td>
</tr>
<tr>
<td>dP/dt@LVP40 (mmHg/s)</td>
<td>9314 ± 401</td>
<td>7116 ± 229</td>
<td>8753 ± 441</td>
<td>7512 ± 529</td>
<td>5656 ± 274</td>
</tr>
<tr>
<td>Right Ventricle (RV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre Surgery (n = 5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RVP (mmHg)</td>
<td>27 ± 1</td>
<td>32 ± 1</td>
<td>52 ± 4</td>
<td>39 ± 2</td>
<td>39 ± 2</td>
</tr>
<tr>
<td>EDP (mmHg)</td>
<td>1.4 ± 0.5</td>
<td>2.4 ± 0.5</td>
<td>9.7 ± 1.6</td>
<td>5.0 ± 0.7</td>
<td>5.8 ± 1.0</td>
</tr>
<tr>
<td>RV min Pressure (mmHg)</td>
<td>0.3 ± 0.3</td>
<td>0.5 ± 0.5</td>
<td>6.2 ± 1.4</td>
<td>1.8 ± 0.9</td>
<td>3.0 ± 0.8</td>
</tr>
<tr>
<td>dP/dt@RVmax (mmHg/s)</td>
<td>2138 ± 177</td>
<td>2088 ± 40</td>
<td>2853 ± 255</td>
<td>2362 ± 280</td>
<td>2021 ± 95</td>
</tr>
<tr>
<td>dP/dt@RVmin (mmHg/s)</td>
<td>−1923 ± 147</td>
<td>−1969 ± 73</td>
<td>−2816 ± 132</td>
<td>−2294 ± 72</td>
<td>−1944 ± 93</td>
</tr>
<tr>
<td>Tau (Weiss, ms)</td>
<td>5.83 ± 0.54</td>
<td>6.84 ± 0.72</td>
<td>9.77 ± 0.92</td>
<td>8.95 ± 0.41</td>
<td>11.56 ± 1.42</td>
</tr>
<tr>
<td>Tau (Glantz, ms)</td>
<td>8.47 ± 1.03</td>
<td>11.97 ± 0.59</td>
<td>13.81 ± 1.00</td>
<td>13.24 ± 0.73</td>
<td>15.18 ± 2.07</td>
</tr>
</tbody>
</table>

LVP, left ventricular pressure; EDP, end diastolic pressure; HR, heart rate; RVP, right ventricular pressure. Values are mean ± SEM. *p < 0.05 vs. age-matched sham. †p < 0.05 vs. previous time point. Bolded numbers draw attention to significance vs. age-matched sham.

TABLE 2 | Invasive hemodynamics from the left and right ventricles in sham.

<table>
<thead>
<tr>
<th></th>
<th>Pre-surgery (n = 9)</th>
<th>2 weeks (n = 11)</th>
<th>4 weeks (n = 9)</th>
<th>9 weeks (n = 11)</th>
<th>18 weeks (n = 13)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Left Ventricle (LV)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LVP (mmHg)</td>
<td>97 ± 2</td>
<td>100 ± 3</td>
<td>103 ± 3</td>
<td>106 ± 4</td>
<td>113 ± 5</td>
</tr>
<tr>
<td>EDP (mmHg)</td>
<td>4.6 ± 1.4</td>
<td>5.0 ± 1.6</td>
<td>5.9 ± 0.8</td>
<td>6.9 ± 2.1</td>
<td>9.9 ± 1.8</td>
</tr>
<tr>
<td>LV min Pressure (mmHg)</td>
<td>−2.8 ± 0.9</td>
<td>−1.4 ± 0.9</td>
<td>−0.2 ± 1.0</td>
<td>0.2 ± 1.1</td>
<td>1.2 ± 1.1</td>
</tr>
<tr>
<td>Systolic Pressure (mmHg)</td>
<td>91 ± 3</td>
<td>95 ± 4</td>
<td>101 ± 4</td>
<td>100 ± 4</td>
<td>110 ± 6</td>
</tr>
<tr>
<td>Diastolic Pressure (mmHg)</td>
<td>64 ± 3</td>
<td>72 ± 4</td>
<td>76 ± 3</td>
<td>75 ± 5</td>
<td>79 ± 4</td>
</tr>
<tr>
<td>dP/dt@LVP40 (mmHg/s)</td>
<td>9838 ± 388</td>
<td>9671 ± 361</td>
<td>9703 ± 324</td>
<td>9478 ± 512</td>
<td>9325 ± 491</td>
</tr>
<tr>
<td>dP/dt@LVP40 (mmHg/s)</td>
<td>9314 ± 401</td>
<td>9077 ± 364</td>
<td>8854 ± 259</td>
<td>8719 ± 474</td>
<td>8718 ± 461</td>
</tr>
<tr>
<td>Right Ventricle (RV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-surgery (n = 5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RVP (mmHg)</td>
<td>27 ± 1</td>
<td>28 ± 1</td>
<td>29 ± 1</td>
<td>29 ± 1</td>
<td>30 ± 1</td>
</tr>
<tr>
<td>EDP (mmHg)</td>
<td>1.4 ± 0.5</td>
<td>1.7 ± 0.4</td>
<td>2.4 ± 0.4</td>
<td>2.2 ± 0.2</td>
<td>2.1 ± 0.5</td>
</tr>
<tr>
<td>RV min Pressure (mmHg)</td>
<td>0.3 ± 0.3</td>
<td>0.3 ± 0.3</td>
<td>1.0 ± 0.2</td>
<td>0.7 ± 0.2</td>
<td>0.9 ± 0.1</td>
</tr>
<tr>
<td>dP/dt@RVmax (mmHg/s)</td>
<td>2038 ± 177</td>
<td>2085 ± 115</td>
<td>2270 ± 176</td>
<td>2722 ± 170</td>
<td>2845 ± 125</td>
</tr>
<tr>
<td>dP/dt@RVmin (mmHg/s)</td>
<td>−1923 ± 147</td>
<td>−1949 ± 107</td>
<td>−1934 ± 93</td>
<td>−2247 ± 84</td>
<td>−2358 ± 77</td>
</tr>
<tr>
<td>Tau (Weiss, ms)</td>
<td>5.83 ± 0.54</td>
<td>6.72 ± 0.49</td>
<td>6.43 ± 0.74</td>
<td>6.20 ± 0.26</td>
<td>5.98 ± 0.31</td>
</tr>
<tr>
<td>Tau (Glantz, ms)</td>
<td>8.47 ± 1.03</td>
<td>9.28 ± 0.95</td>
<td>9.58 ± 0.33</td>
<td>9.19 ± 0.96</td>
<td>8.52 ± 0.41</td>
</tr>
</tbody>
</table>

LVP, left ventricular pressure; EDP, end diastolic pressure; HR, heart rate; RVP, right ventricular pressure. Values are mean ± SEM. *p < 0.05 vs. pre-surgery values. †p < 0.05 vs. previous time point. Bolded numbers draw attention to significance vs. pre-surgery values.
FIGURE 2 | Ventricular interstitial fibrosis in both ventricles over 18 weeks of TAC. (A) Representative images stained with Picrosirius Red (top panel; left ventricle; LV, bottom panel; right ventricle; RV). (B) Average interstitial fibrosis over time in both ventricles (n = 6 for each point). Sham was unchanged over 18 weeks and was represented by the point at x = 0. *p < 0.05 vs. age-matched sham. †p < 0.05 vs. previous time point. Linear regression was run on correlations between average fibrosis and all invasive indices of diastolic function: (C) LV end diastolic pressure (LV EDP), (D) RV end diastolic pressure (RV EDP), (E) LV dP/dt max, (F) LV dP/dt max, (G) LV Tau Glantz, (H) LV Tau Weiss, (I) RV dP/dt max, (J) RV Tau Glantz, (K) RV Tau Weiss.

weighed and normalized to tibial length (TL). Weights were normalized to TL as increasing BW skewed the HW/BW ratio in sham mice, while HW/TL in the same mice was stable across normal growth (Figure 3). Representative H&E (top panel) and PSR (bottom panels) cross-sectional images of the heart are presented in Figure 4A. Whole heart hypertrophy increased steadily (Figure 4B), culminating in significantly larger hearts by 18 weeks of TAC (Figure 4C). To evaluate chamber-specific hypertrophy, atrial, LV, RV and septal weights were normalized to TL. The atrial/TL and LV/TL ratio increased steadily across all time points (Figures 4D,E). RV/TL did not increase until 4 weeks of TAC (Figure 4F) while the septum/TL ratio increased to 4 weeks where it plateaued and increased proportional to sham out to 18 weeks (Figure 4G). Expanded morphometrics are presented in Table 3 (TAC) and Table 4 (sham).

To quantify concentric hypertrophy, cardiomyocyte CSA was assessed in both the LV and RV (Figure 5). LV CSA increased progressively over 18 weeks, while RV CSA only increased between 2 and 4 weeks, remaining stable thereafter (Figure 5B). The linear increase in LV weight and LV CSA over 18 weeks suggested the rate of hypertrophy was constant and likely (predominantly) concentric (Figure 5C).
In contrast, the pattern in the RV had two parts. Initially (0–4 weeks), RV CSA and weight increased linearly (Figure 5D). Between 4 and 18 weeks, however, RV weight continued to increase while RV CSA plateaued. While this increased weight could be attributed to extracellular proteins or cardiomyocyte hyperplasia, RV fibrosis was static between 4 and 18 weeks (Figure 2B) and, adult cardiomyocyte hyperplasia is accepted to be low to negligible. This suggested the weight was coming from an increase in cardiomyocyte cell length (i.e., eccentric hypertrophy).
TABLE 3 | Morphometric characteristics of TAC mice.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre-surgery (n = 11)</th>
<th>2 weeks (n = 16)</th>
<th>4 weeks (n = 16)</th>
<th>9 weeks (n = 15)</th>
<th>18 weeks (n = 14)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BW (g)</td>
<td>37.2 ± 0.7</td>
<td>40.4 ± 3.1*</td>
<td>40.8 ± 3.1*</td>
<td>45.2 ± 7.2*</td>
<td>44.1 ± 7.1*</td>
</tr>
<tr>
<td>TL (cm)</td>
<td>1.84 ± 0.02</td>
<td>1.84 ± 0.04</td>
<td>1.87 ± 0.03</td>
<td>1.90 ± 0.03</td>
<td>1.93 ± 0.03</td>
</tr>
<tr>
<td>Heart Weight (mg)</td>
<td>152 ± 4</td>
<td>200 ± 24</td>
<td>235 ± 30</td>
<td>270 ± 40</td>
<td>312 ± 59</td>
</tr>
<tr>
<td>Atria Weight (mg)</td>
<td>9 ± 1</td>
<td>16 ± 6</td>
<td>20 ± 7</td>
<td>25 ± 12</td>
<td>36 ± 18</td>
</tr>
<tr>
<td>LV Weight (mg)</td>
<td>79 ± 3</td>
<td>98 ± 8</td>
<td>112 ± 24</td>
<td>128 ± 17</td>
<td>156 ± 16</td>
</tr>
<tr>
<td>LV CSA (µm²)</td>
<td>189 ± 15</td>
<td>296 ± 19</td>
<td>373 ± 44</td>
<td>471 ± 52</td>
<td>658 ± 87</td>
</tr>
<tr>
<td>RV Weight (mg)</td>
<td>35 ± 2</td>
<td>36 ± 5</td>
<td>45 ± 9</td>
<td>54 ± 13</td>
<td>59 ± 11</td>
</tr>
<tr>
<td>RV CSA (µm²)</td>
<td>150 ± 14</td>
<td>168 ± 9</td>
<td>234 ± 14</td>
<td>237 ± 12</td>
<td>241 ± 17</td>
</tr>
<tr>
<td>Septum Weight (mg)</td>
<td>37 ± 3</td>
<td>49 ± 7</td>
<td>57 ± 10</td>
<td>60 ± 5</td>
<td>66 ± 9</td>
</tr>
<tr>
<td>Lung Wet Weight (mg)</td>
<td>221 ± 12</td>
<td>230 ± 49</td>
<td>273 ± 73</td>
<td>349 ± 152</td>
<td>450 ± 187</td>
</tr>
<tr>
<td>Lung Wet/Dry Ratio</td>
<td>4.23 ± 0.09</td>
<td>4.26 ± 0.86</td>
<td>4.34 ± 0.58</td>
<td>4.30 ± 0.67</td>
<td>4.23 ± 0.94</td>
</tr>
<tr>
<td>Kidney Weight avg (mg)</td>
<td>269 ± 10</td>
<td>269 ± 37</td>
<td>272 ± 39</td>
<td>295 ± 42</td>
<td>316 ± 72</td>
</tr>
<tr>
<td>Spleen Weight (mg)</td>
<td>97 ± 6</td>
<td>139 ± 27</td>
<td>113 ± 15</td>
<td>128 ± 28</td>
<td>171 ± 35</td>
</tr>
<tr>
<td>Liver Weight (g)</td>
<td>1.68 ± 0.14</td>
<td>1.87 ± 0.13</td>
<td>1.89 ± 0.32</td>
<td>2.08 ± 0.44</td>
<td>2.07 ± 0.24</td>
</tr>
</tbody>
</table>

BW, body weight; TL, tibial length; LV, left ventricle; RV, right ventricle; Values are mean ± SD. *p < 0.05 vs. age-matched sham. †p < 0.05 vs. previous time point. Bolded numbers draw attention to significance vs. age-matched sham.

TABLE 4 | Morphometric characteristics of sham mice.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre-surgery (n = 11)</th>
<th>2 weeks (n = 8)</th>
<th>4 weeks (n = 10)</th>
<th>9 weeks (n = 9)</th>
<th>18 weeks (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BW (g)</td>
<td>37.2 ± 2.3</td>
<td>40.4 ± 3.1*</td>
<td>44.0 ± 4.2*</td>
<td>51.0 ± 7.0*</td>
<td>55.1 ± 10.0*</td>
</tr>
<tr>
<td>TL (cm)</td>
<td>1.84 ± 0.05</td>
<td>1.85 ± 0.03</td>
<td>1.88 ± 0.03</td>
<td>1.91 ± 0.02</td>
<td>1.92 ± 0.04</td>
</tr>
<tr>
<td>Heart Weight (mg)</td>
<td>158 ± 14</td>
<td>171 ± 10*</td>
<td>181 ± 9*</td>
<td>191 ± 14*</td>
<td>200 ± 16*</td>
</tr>
<tr>
<td>Atria Weight (mg)</td>
<td>9 ± 2</td>
<td>10 ± 2</td>
<td>11 ± 1</td>
<td>11 ± 1</td>
<td>12 ± 3*</td>
</tr>
<tr>
<td>LV Weight (mg)</td>
<td>79 ± 7</td>
<td>83 ± 10</td>
<td>85 ± 9</td>
<td>88 ± 8</td>
<td>91 ± 3</td>
</tr>
<tr>
<td>LV CSA (µm²)</td>
<td>189 ± 15</td>
<td>191 ± 11</td>
<td>196 ± 13</td>
<td>209 ± 12</td>
<td>213 ± 13</td>
</tr>
<tr>
<td>RV Weight (mg)</td>
<td>32 ± 5</td>
<td>37 ± 6</td>
<td>41 ± 2*</td>
<td>44 ± 3*</td>
<td>45 ± 2*</td>
</tr>
<tr>
<td>RV CSA (µm²)</td>
<td>150 ± 9</td>
<td>154 ± 10</td>
<td>160 ± 11</td>
<td>166 ± 10</td>
<td>171 ± 12</td>
</tr>
<tr>
<td>Septum Weight (mg)</td>
<td>37 ± 6</td>
<td>41 ± 7</td>
<td>44 ± 8</td>
<td>48 ± 8*</td>
<td>52 ± 7*</td>
</tr>
<tr>
<td>Lung Wet Weight (mg)</td>
<td>221 ± 28</td>
<td>235 ± 32</td>
<td>252 ± 17</td>
<td>238 ± 44</td>
<td>235 ± 48</td>
</tr>
<tr>
<td>Lung Wet/Dry Ratio</td>
<td>4.23 ± 0.23</td>
<td>4.25 ± 0.71</td>
<td>4.51 ± 0.16</td>
<td>4.30 ± 0.42</td>
<td>4.49 ± 0.70</td>
</tr>
<tr>
<td>Kidney Weight avg (mg)</td>
<td>269 ± 24</td>
<td>305 ± 23</td>
<td>318 ± 18</td>
<td>335 ± 30</td>
<td>342 ± 31</td>
</tr>
<tr>
<td>Spleen Weight (mg)</td>
<td>97 ± 14</td>
<td>112 ± 16*</td>
<td>107 ± 15</td>
<td>115 ± 9*</td>
<td>133 ± 7*</td>
</tr>
<tr>
<td>Liver Weight (g)</td>
<td>1.68 ± 0.34</td>
<td>1.99 ± 0.16</td>
<td>2.10 ± 0.29*</td>
<td>2.24 ± 0.36</td>
<td>3.01 ± 0.65*</td>
</tr>
</tbody>
</table>

BW, body weight; TL, tibial length; LV, left ventricle; RV, right ventricle; Values are mean ± SD. *p < 0.05 vs. pre-surgery values. †p < 0.05 vs. previous time point. Bolded numbers draw attention to significance vs. pre-surgery values.

Temporal Echocardiography Revealed an Early Period of Stable Cardiac Output Followed by a Secondary Decline and Chamber Dilatation

Representative M-mode images from the LV of sham and TAC mice are profiled in Figure 6A. LV dilation (increased LV end diastolic dimensions) began at 4 weeks and progressed to 18 weeks (Figure 6B). Cardiac output decreased by 2 weeks and remained stable until 9 weeks before decreasing further by 18 weeks (Figure 6C). Ejection fraction, a common variable used to clinically grade LV function, followed the same pattern as cardiac output with the secondary decline occurring between 9 and 18 weeks (Figure 6D). Complete echocardiographic data from sham and TAC mice is summarized in Table 5.

Pathological Remodeling of the Pulmonary Vasculature Was Progressive With Significant Muscularization of Smaller Vessels

To confirm the increase in RVP was pathological, we looked for evidence of pulmonary vascular remodeling within the
FIGURE 5 | Cardiomyocyte cross-sectional area (CSA) from both the left (LV) and right (RV) ventricles over 18 weeks of TAC. (A) Representative images from the LV (top row) and RV (bottom row) stained with wheat germ agglutinin-3. (B) Averaged cardiomyocyte CSA over 18 weeks of TAC \( (n=6 \text{ for each point}) \). Complete sham CSA data is presented in Table 4. Correlation plots between ventricle weight and CSA in the (C) LV and (D) RV. \( ^* p < 0.01 \) vs. age-matched sham. \( ^\dagger p < 0.01 \) vs. previous time point.

FIGURE 6 | Chamber size and echocardiographic function over 18 weeks of TAC. (A) Representative M-mode images acquired from the mid-papillary region of the LV. (B) Left ventricular end diastolic (EDD) and end systolic (ESD) dimensions, (C) cardiac output and (D) ejection fraction demonstrate dilation and a decline in cardiac function, especially between the 9 and 18 week time-points. Heart rate was statistically unchanged between all time points. \( ^* p < 0.01 \) vs. age-matched sham. \( ^\dagger p < 0.01 \) vs. previous time point.

pulmonary circulation by histology (Figure 7A). We found increased large-vessel wall thickness by 2 weeks with a neomuscularization of the smaller vessels by 4 weeks; both continuously increased thereafter (Figures 7B,C). By 9 weeks, this was associated with an increased total lung weight without evidence of pulmonary edema (i.e., static lung wet/dry weight ratio; Table 2). Pulmonary vascular resistance, calculated using the formula \( PVR = (RVP-LV \ EDP)/\text{cardiac output} \), was reduced at 2 weeks, before peaking at 4 weeks and remaining elevated thereafter (Figure 7D).

**DISCUSSION**

This study is the first to report a longitudinal, biventricular evaluation of cardiac function and morphology in the
TABLE 5 | Expanded echocardiographic function.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre-surgery (n = 8)</th>
<th>2 weeks (n = 15)</th>
<th>4 weeks (n = 12)</th>
<th>9 weeks (n = 17)</th>
<th>18 weeks (n = 13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dimension (mm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diastolic</td>
<td>4.38 ± 0.04</td>
<td>4.39 ± 0.04</td>
<td>4.66 ± 0.07(\dagger)</td>
<td>4.78 ± 0.07(\ast)</td>
<td>5.11 ± 0.09(\dagger)</td>
</tr>
<tr>
<td>Systolic</td>
<td>2.95 ± 0.01</td>
<td>3.43 ± 0.05(\dagger)</td>
<td>3.74 ± 0.08(\dagger)</td>
<td>3.86 ± 0.12(\ast)</td>
<td>4.49 ± 0.13(\dagger)</td>
</tr>
<tr>
<td>Volumetric (µL)</td>
<td>86.9 ± 1.8</td>
<td>87.1 ± 1.8</td>
<td>100.9 ± 3.3(\dagger)</td>
<td>107.2 ± 3.8(\ast)</td>
<td>124.9 ± 4.9(\dagger)</td>
</tr>
<tr>
<td>Volumetric (µL)</td>
<td>33.5 ± 0.4</td>
<td>48.6 ± 1.6(\dagger)</td>
<td>60.0 ± 3.1(\dagger)</td>
<td>65.6 ± 4.9(\ast)</td>
<td>93.4 ± 5.9(\dagger)</td>
</tr>
<tr>
<td>Stroke Volume (µL)</td>
<td>53.4 ± 1.6</td>
<td>38.5 ± 1.3(\dagger)</td>
<td>40.8 ± 2.3(\dagger)</td>
<td>41.6 ± 1.6(\ast)</td>
<td>31.5 ± 2.0(\dagger)</td>
</tr>
<tr>
<td>Ejection Fraction (%)</td>
<td>61.3 ± 0.7</td>
<td>44.3 ± 1.2(\dagger)</td>
<td>40.6 ± 2.1(\dagger)</td>
<td>39.9 ± 2.4(\ast)</td>
<td>26.1 ± 2.2(\dagger)</td>
</tr>
<tr>
<td>Fractional Shortening (%)</td>
<td>32.7 ± 0.5</td>
<td>21.8 ± 0.8(\dagger)</td>
<td>19.9 ± 1.1(\dagger)</td>
<td>19.6 ± 1.3(\ast)</td>
<td>12.3 ± 1.1(\dagger)</td>
</tr>
<tr>
<td>Cardiac Output (mL/min)</td>
<td>29.1 ± 0.5</td>
<td>21.9 ± 0.7(\dagger)</td>
<td>23.6 ± 1.3(\dagger)</td>
<td>22.8 ± 0.8(\ast)</td>
<td>22.8 ± 0.8(\dagger)</td>
</tr>
<tr>
<td>Wall Thickness (mm)</td>
<td>0.88 ± 0.02</td>
<td>1.15 ± 0.01(\dagger)</td>
<td>1.20 ± 0.01(\dagger)</td>
<td>1.23 ± 0.01(\ast)</td>
<td>1.30 ± 0.02(\dagger)</td>
</tr>
<tr>
<td>Heart Rate (bpm)</td>
<td>548 ± 10</td>
<td>570 ± 7</td>
<td>578 ± 13</td>
<td>557 ± 6</td>
<td>575 ± 11(\dagger)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pre-surgery (n = 8)</th>
<th>2 weeks (n = 8)</th>
<th>4 weeks (n = 8)</th>
<th>9 weeks (n = 9)</th>
<th>18 weeks (n = 12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dimension (mm)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diastolic</td>
<td>4.38 ± 0.04</td>
<td>4.39 ± 0.04</td>
<td>4.44 ± 0.04</td>
<td>4.50 ± 0.07</td>
<td>4.62 ± 0.04(\dagger)</td>
</tr>
<tr>
<td>Systolic</td>
<td>2.95 ± 0.01</td>
<td>2.99 ± 0.04</td>
<td>3.05 ± 0.06</td>
<td>3.05 ± 0.08</td>
<td>3.19 ± 0.06(\dagger)</td>
</tr>
<tr>
<td>Volumetric (µL)</td>
<td>86.9 ± 1.8</td>
<td>87.5 ± 1.9</td>
<td>89.5 ± 1.9</td>
<td>92.6 ± 3.7</td>
<td>98.6 ± 1.8(\dagger)</td>
</tr>
<tr>
<td>Volumetric (µL)</td>
<td>33.5 ± 0.4</td>
<td>34.8 ± 1.2</td>
<td>36.6 ± 1.7</td>
<td>36.8 ± 2.5</td>
<td>41.0 ± 1.8(\dagger)</td>
</tr>
<tr>
<td>Stroke Volume (µL)</td>
<td>53.4 ± 1.6</td>
<td>52.7 ± 1.0</td>
<td>52.9 ± 1.2</td>
<td>55.8 ± 1.4</td>
<td>57.7 ± 0.9(\dagger)</td>
</tr>
<tr>
<td>Ejection Fraction (%)</td>
<td>61.3 ± 0.7</td>
<td>60.3 ± 0.7</td>
<td>59.1 ± 1.4</td>
<td>60.6 ± 1.2</td>
<td>58.7 ± 1.2</td>
</tr>
<tr>
<td>Fractional Shortening (%)</td>
<td>32.7 ± 0.5</td>
<td>32.0 ± 0.5</td>
<td>31.2 ± 0.7</td>
<td>32.3 ± 0.8</td>
<td>31.0 ± 0.8</td>
</tr>
<tr>
<td>Cardiac Output (mL/min)</td>
<td>29.1 ± 0.5</td>
<td>29.2 ± 0.6</td>
<td>29.2 ± 0.6</td>
<td>30.3 ± 0.8</td>
<td>30.8 ± 0.3(\dagger)</td>
</tr>
<tr>
<td>Wall Thickness (mm)</td>
<td>0.88 ± 0.02</td>
<td>0.92 ± 0.03</td>
<td>0.94 ± 0.03(\dagger)</td>
<td>0.97 ± 0.03(\dagger)</td>
<td>0.99 ± 0.04(\dagger)</td>
</tr>
<tr>
<td>Heart Rate (bpm)</td>
<td>548 ± 10</td>
<td>554 ± 7</td>
<td>552 ± 11</td>
<td>544 ± 8</td>
<td>535 ± 7</td>
</tr>
</tbody>
</table>

\(\dagger\) p < 0.05 vs. age-matched sham mice. \(\ast\) p < 0.05 vs. previous time point. \(\text{#}\) p < 0.05 in sham vs. pre-surgery time point. Bolded values draw attention to significance vs. age-matched sham (top) and to significance vs. pre-surgery values (bottom).

murine pressure-overload model. Here we mapped the pathophysiological development of type II pulmonary hypertension, pulmonary vascular remodeling and RV dysfunction in TAC for the first time. There were two phases of function, compensatory and decompensatory. In the compensatory phase, both the LV and RV remodeled concentrically in line with increased pressure. During decompensation, the LV continued to hypertrophy concentrically despite declining pressure, while in the RV the data suggested a shift to eccentric hypertrophy. We also demonstrated that no one parameter was sufficient to explain diastolic function with each index (e.g., fibrosis, EDP, tau and dP/dt\(\text{min}\)) following a different pattern over time. And finally, fibrosis did not correlate with diastolic pressure in either ventricle over time, calling into question how fibrosis per se is related to elevations in EDP.

**Left Ventricular Perspective**

TAC is commonly used to investigate LV hypertrophy as pressure drives proportional concentric cardiac growth (Grossman et al., 1975). The relationship between pressure and hypertrophy over time, however, is more complex. In this model, we show early LV hypertrophy was concentric and proportional to pressure (0–4 weeks), but during decompensation (4–18 weeks), concentric hypertrophy persisted despite declining systolic pressures. While the former is well recognized in the literature, the latter (i.e., hypertrophy with declining pressure) is typically only reported at very late time points or in more severe models (Norton et al., 2002; Rothermel et al., 2005; Chen et al., 2012; Mohammed et al., 2012). Thus, pressure-independent hypertrophy is relative and a hallmark of decompensation. Importantly, we confirm the type of hypertrophy during decompensation as concentric. Cardiac hypertrophy is an independent risk factor for cardiovascular morbidity and mortality (Levy et al., 1990), and a primary target of emerging HF therapies (Frey et al., 2004). To our knowledge however, the molecular mechanism(s) by which cardiomyocytes undergo concentric hypertrophy through these two stages have not been directly compared and contrasted. The existence of two phases of concentric hypertrophy is relevant because anti-hypertrophic therapies are often initiated early in a model (e.g., Takimoto et al., 2005). This leaves the impact of therapies in the decompensated stage of cardiac remodeling largely unknown; therapies initiated in this later phase may not have the same outcome as those initiated early on. This is particularly important given the aged clinical population that largely presents after years of hypertrophic remodeling, only as their failing heart begins to precipitate symptoms. As these patients are approaching—or already experiencing—decompensation, comparatively assessing therapies between the compensatory and decompensatory phases is an important future focus of pressure-overload studies.

Both LV hypertrophy and eventual decompensation are ubiquitous following pressure-overload. The variability is in the
of constriction (gauge of needle) impacts both the amount of hypertrophy and rate of dilation. Smaller gauges [i.e., 24-gauge (Pradhan et al., 2016), 25-gauge (van Nierop et al., 2013)] lead to mild concentric hypertrophy, no early dilation and mild dysfunction. Intermediate gauges [i.e., 27-gauge (Nakamura et al., 2001; Liao et al., 2002; van Nierop et al., 2013)] lead to more substantial short-term hypertrophy, a period of stable or recovered cardiac function, and then dilation and decompensation within 4 to 9 weeks. Severe constrictions (28-gauge, Rothermel et al., 2005) develop concentric hypertrophy in tandem with rapid dilatation and mortality. Second, animal selection significantly affects the response to pressure-overload. Strain and gender differences contribute to the genetic variation (Barrick et al., 2007, 2009), while different ages and/or weights impact the relative severity of the same-sized constriction (e.g., 27-gauge induces a 20% increase in LV weight by 3 weeks in 6–8 weeks old mice (Rothermel et al., 2005) versus a 50% increase in 14–16 weeks old mice (Kapur et al., 2012)]. Third, and finally, the relative proximity of the band to the heart (i.e., ascending vs. transverse vs. abdominal aortic constriction) also impacts the magnitude of hypertrophy and rate of decompensation (Foster et al., 2017). These data indicate the need for direct intra-study comparisons of hypertrophy and its molecular mechanisms, and that inter-study comparisons be made with these factors in mind. Here, we report early concentric hypertrophy and recovered
FIGURE 9 | An artistic depiction of the hypertrophic response in both ventricles over 18 weeks of TAC. At 4 weeks, both the right (RV) and left (LV) ventricles present with concentric hypertrophy (thickening of ventricle walls with an increase in cardiomyocyte cross-sectional area (CSA)). LV concentric hypertrophy continued out to 18 weeks despite declining systolic pressures. Alternatively, RV cardiomyocyte CSA was static despite sustained systolic pressure-overload. Here, total weight increased in the absence of changes in CSA, suggestive of cardiomyocyte lengthening (eccentric hypertrophy).

function (0–4 weeks) before dilatation and decompensation (18 weeks). These data suggest our model was moderate, and thus valuable to investigate the transitional phase between compensatory remodeling and decompensated HF.

Interstitial fibrosis correlates with a stiffening of the LV wall, which impairs ventricular relaxation and contributes (among other things) to increased passive filling pressures (EDP) (Jalil et al., 1989; Weber et al., 1993; Conrad et al., 1995; Yamamoto et al., 2002; Kass et al., 2004; Matsusaka et al., 2006). Increased EDP is part of the diagnosis of diastolic dysfunction (Mandinov et al., 2000; Paulus et al., 2007), thus any cause of increased EDP is a clinically important event. Here we show that over time, an increase in EDP was neither dependent on a change in interstitial fibrosis, nor guaranteed by an increase in interstitial fibrosis. In the LV, fibrosis increased from 7 to 11% between 2 and 18 weeks without commensurate increases in EDP. In the RV, fibrosis increased 5-fold by 2 weeks while EDP remained unchanged. Interestingly, other reports have described disagreement between the onset and severity of fibrosis and the relative diastolic pressures. Wu et al. (2011) reported a threefold increase in LV fibrosis in their model without any change in EDP. Hamdani et al. (2014) reported increased left ventricular interstitial fibrosis in a diabetic model in the absence of changes to EDP. A study by Perrino (2006), reported variable LV interstitial fibrosis with static LVEDP in three different TAC groups. And finally, treating with sildenafil to reduce fibrosis twofold in a TAC model did not alter EDP (Pradhan et al., 2016). These data suggest gross fibrosis does not explain changes in diastolic pressure in TAC. For example, collagen cross-linking is more predictive of LV stiffness and diminished diastolic function than total collagen content, both in experimental models (Badenhorst, 2003; López et al., 2012) and in humans (Ravassa et al., 2017). What remains to be established is a definitive approach to capturing ECM remodeling related to diastolic dysfunction, which will be critical in developing future therapies.

In shams, we report appreciable changes in cardiac structure and function over the 18 week study period. This was especially true in the RV, where between 2 and 9 weeks invasive measures of contractility and relaxation increased by ∼33%. In the same time frame, the change in LV function was <10%. This suggests the healthy RV may reach functional maturity in a different timeframe than the LV. Importantly, evidence of contractile dysfunction in the TAC RV was only significant by 18 weeks because of the increase in RV function in aged-matched shams. This demonstrates the importance of mapping structure and function in shams/controls, particularly in longitudinal...
Right Ventricular Perspective

Type-II pulmonary hypertension is the most prevalent form of pulmonary hypertension (Rosenkranz et al., 2016). Reported in over 50% of HF patients (Hoeper et al., 2005, 2009; Lam et al., 2009), its presence increases 3-year mortality by 20–50% (positively correlated with severity of pulmonary hypertension) (Bogaard et al., 2009). While numerous models exist for investigating the pathophysiology and treatment options for type-I pulmonary hypertension, the literature on experimental models of type-II pulmonary hypertension is comparatively sparse (Stenmark et al., 2009). In type-II pulmonary hypertension, the primary condition is LV dysfunction; increased LV filling pressures (EDP) precede the increase in pulmonary artery pressures (Adusumalli and Mazurek, 2017). This differs etiologically from type I pulmonary hypertension, which originates as a primary pathology of the pulmonary vasculature (Simonneau et al., 2009). Here, we corroborate previous findings demonstrating pulmonary hypertension and RV dysfunction are prominent features of the LV pressure-overload model (Chen et al., 2012).

We further verified that the onset of pulmonary hypertension was secondary to the increase in EDP, and that pathological remodeling in the pulmonary vasculature was secondary to the spike in RVP. This confirms TAC is a model of type II pulmonary hypertension with the instigating pathology in the LV, which migrates to the RV and associated vasculature. As current therapies for type I pulmonary hypertension (i.e., pulmonary vasodilators) are either ineffective (Naeije and Huez, 2007) or detrimental (Guazzi and Arena, 2010) in patients with HF (type II), there is an urgent need for novel therapies that address this population. TAC presents an ideal model to investigate both the pathophysiology of type II pulmonary hypertension, as well as novel treatments for this prevalent condition.

Remodeling patterns in the LV cannot be applied to the RV; the RV is developmentally (Zaffran, 2004), physiologically (Littlejohns et al., 2014), and molecularly (Fields et al., 1978) distinct from the LV and pumps into a different vascular bed against differing hemodynamic loads. Here we report early concentric hypertrophy between 2 and 4 weeks that occurred in tandem with increased RVP, followed by a secondary phase where RV weight increased without any further increase in cardiomyocyte CSA–suggestive of a shift to eccentric hypertrophy. The lack of concentric hypertrophy was unexpected given sustained pulmonary hypertension. This contrasted the LV where cardiomyocyte CSA increased out to 18 weeks despite declining pressures and suggests the RV does not respond similarly to the stimuli driving continued concentric growth in the late-stage LV. Emerging studies suggest RV hypertrophy may be determinant to mortality; a defining feature of decompensation is a disproportionate increase in RV mass compared to LV mass (Bing et al., 1995; Norton et al., 2002; Brooks et al., 2010; Chen et al., 2012). Generally, cardiac hypertrophy studies are LV-centric (Weeks and McMullen, 2011; Maillet et al., 2013) and more attention should be provided to the RV.

The RV is, at least in part, hemodynamically dependent on the LV (Santamore and Dell’Italia, 1998). One example of this is in the flow across the lung, which is a function of the pressure gradient between the RV (RVP) and the LV (LVEDP). An increase in LVEDP is thought to cause a reflexive increase in RVP for the maintenance of flow through the pulmonary system (Chen et al., 2012). Our analysis does not show this to be entirely true as a curvilinear relationship is a better fit (Figure 8). This may be due to extensive recruitment and distension of pulmonary capillaries to reduce pulmonary vascular resistance in early situations of elevated EDP.

Finally, in light of the varying patterns between the LV and RV with regards to pressure and hypertrophy, we introduce an updated depiction of hypertrophy progression in pressure-overload (Figure 9).

Diastolic Dysfunction

The concept of “diastolic dysfunction,” which grew out of clinical observation, is cumbersome to diagnose and a validated gold standard is missing. Indeed, what we define as dysfunction is only in terms of referencing ‘normal’ function, which is dynamic as the cardiovascular system develops and ages. In experimental models, the standard is to measure diastolic function invasively (e.g., EDP, dP/dt_{min}, and Tau). This differs from the clinical reliance on indirect surrogate measures (e.g., symptoms, E/A ratio and serum BNP levels). Of concern is whether the surrogate measurements remain in agreement with the fundamental pathophysiology. We found over time, diastolic function was not easily reconciled by any one parameter, suggesting diastolic dysfunction is more a spectrum of impairments than a singular entity.

As components of diastolic function, we interpret EDP as a measure of pressure-stress to relaxation, Tau as the relative time required for relaxation, and dP/dt_{min} as the instantaneous maximum rate-of-relaxation. We show that diastolic parameters were incongruent with each other over time, a finding reported in other pressure-overload studies (Takimoto et al., 2005; Perrino, 2006; Chen et al., 2012). Indeed, each parameter likely has subtle and unique inferential value. If both EDP and Tau are increased, is this the same disease state as increased EDP when Tau is unchanged? As most studies rely on a single parameter to assess diastolic function, this question remains difficult to answer. Caution should be taken when evaluating development of diastolic dysfunction in different etiologies (e.g., channelopathy vs. interstitial fibrosis) as they may not conform to a single diastolic measure. Rather, each measure likely varies in sensitivity to identify dysfunction, or captures a particular physiological nuance of diastolic function.

One discrepancy to highlight is the difference in sensitivity between Tau methods to assess diastolic function. Particularly, Tau Glantz (Tau_{GL}) detected diastolic impairments by 2 weeks while Tau Weiss (Tau_{W}) was unchanged. The discrepancy between Tau measures may exist because Tau_{W} (approximated in isolated hearts) assumes an independence of Tau from volume loading and changes in EDP (Weiss et al., 1976). Tau_{GL}, however, is an updated method derived from observations in intact dog hearts, and accounts for the impact of variable loading conditions.
(i.e., changing diastolic pressures) (Raff and Glantz, 1981). Given
the chronically elevated EDP in our (and most) pressure overload
model(s), Tau\_C may be the more sensitive parameter. Yet, it
remains uncertain at this time which is the superior measure
that avoids type-I/II statistical errors and, thus, until more
physiological studies are performed, both measures should be
used with a clear knowledge as to their underlying assumptions.

Additionally, it was unexpected that in sham mice, while
systolic function remained stable, the thresholds for diastolic
dysfunction were met (EDP, dP/dt\_min, and Tau\_C decreased
from pre-surgical values). This is consistent with human data
where diastolic function is more fragile with aging than systolic
function (Fischer et al., 2003). These steady declines suggest the
“thresholds” used to identify diastolic dysfunction may need to be
adjusted in each study based on reference values relative to aging.

Finally, parameters for grading diastolic function in the LV
were also impaired in the RV following TAC. However, RV
diastolic dysfunction remains largely undefined, both clinically
and in basic research, and gold standard indices of RV diastolic
function remain to be determined in a patient population (Axell
et al., 2015).

**Congestion in Pressure-Overload**

HF, either clinically or experimentally, is not defined by the
presence or absence of pulmonary edema. Indeed, congestion
is neither always expected in HF nor always due to pulmonary
edema. In fact, pulmonary edema is rare in patients with HF
(Mahdyoon et al., 1989; Tarvastmäki et al., 2014; Melensovsky
et al., 2015), particularly when compared to the reference values
in age-matched individuals without HF (Kataoka and Matsuno,
2008). This is sometimes despite the presence of hemodynamic
congestion (this was part of the motivation to shift terminology
from congestive HF to HF with preserved or reduced ejection
fraction). Consistent with HF patients, a feature of TAC is
congestion without pulmonary edema (Chen et al., 2012; Foster
et al., 2017). This is not to say that pulmonary edema never occurs
in experimental models of HF. Both in our study and in others,
pulmonary edema is observed along with rapid decompensation
instead of reaching pre-determined time-points (Inoko et al.,
1994; Kihara and Sasayama, 1997; Siri et al., 1997; Chung et al.,
1998; van Nierop et al., 2013). Thus, when present, pulmonary
edema in rodent models may be more indicative of impending
mortality than part of the pathophysiology of morbidity.

**Limitations**

While we characterize cardiac function and morphology across
multiple time points, we do so in young healthy male mice
when the clinical HF population is variably aged and both
sexes. Indeed, the necessary next step is to apply this ‘mapping’
approach using aged male and female subjects. Future pre-clinical
models might also benefit from an assessment of frequently used
clinical variables such as blood biomarkers (i.e., BNP; Doust
et al., 2005), Doppler echo, or frailty indexes (Singh et al., 2014)
to further improve the alignment between experimental models
and the clinical population. As well, isolated cardiomyocyte
measurements of length and width would provide insight into
eccentric hypertrophy.

**Future Outlook**

The goal of HF research is to translate findings to the clinical
population to improve survival and quality of life. As too
few drugs make the transition from bench to bedside (Mak
et al., 2014; Fernández-Avilés et al., 2018), there is a need to
improve the success of translational research. Several reports have
emphasized that the current designs of præclinical rodent studies
are not fundamentally rigorous enough (Kloner, 2013; Ovize
et al., 2013; Vander Heide and Steenbergen, 2013). This demands
an improved understanding of the basic pathophysiology of
the models used to investigate preclinical therapies (Houser
et al., 2012). A bi-ventricular temporal assessment incorporating
multiple indices of diastolic function addresses this in part,
adding to our understanding of pressure-overload HF and
specifically the time course of pathology in the RV.

**AUTHOR CONTRIBUTIONS**

MP, JH, KB, and JS conceptualized the study, designed the
experiments, drafted the manuscript, critically revised the
manuscript for intellectual content, and gave the final approval
for the article. MP, NR, and JH conducted the experiments. All
authors analyzed and/or interpreted the experimental results and
read and gave permission to the final draft of the manuscript.

**FUNDING**

This work was supported by grants from National Science
Research Engineering Council (KB and JS), a Canadian Institutes
of Health Research grant (MOP 111159 to JS), and a Heart
and Stroke Foundation of Canada grant (JS and KB). JS is
also a New Investigator of the Heart and Stroke Foundation
of Canada. We further acknowledge the philanthropic support for
cardiovascular research from Betty and Jack Southen, of London
ON and from Matthew O’Hara, of Guelph ON to the laboratory
of JS.

**ACKNOWLEDGMENTS**

We sincerely thank Ian Smith for his generation of Figure 9.

**REFERENCES**

ventricular cardiomyopathy: is it the result or cause of disease progression?

Allwood, M. A., Kinobe, R. T., Ballantyne, L., Romanova, N., Melo, L. G., Ward,
with aging and pressure overload but is protective against isoproterenol-
j.carpath.2014.03.007


failure with preserved ejection fraction. *Hypertension* 47, 901–911. doi: 10.1161/01.HYP.0000215579.81408.8e


**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2018 Platt, Huber, Romanova, Brunt and Simpson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**